GlobeImmune's Tarmogen plus SOC shows 94% EVR

12-week Phase II trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular Tarmogen (immunogen) for hepatitis C  virus infection, had a 94% early virologic response rate.

Presented at the annual meeting of the European Association for the  Study of the Liver in Copenhagen, Denmark, the study compared GI-5005  plus standard of care - pegylated interferon and ribavirin - versus SOC  alone in patients with chronic genotype 1 hepatitis C infection.

"We were pleased to see a 94% EVR rate in the treatment naive patient  population," said Eric Lawitz, the study's lead author. "We believe that  this increase in EVR over standard-of-care alone may indicate that the  GI-5005 mechanism of action is complementary to the current standard  care," he added.